Developer docs
API playgroundTry for free, no card

Search company profiles

NanoPass Technologies

Full company profile

uuid0002lnn

Namestring
NanoPass Technologies
Legal namestring
NanoPass Technologies Ltd.
Websiteurl
nanopass.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

NanoPass Technologies Ltd. is a privately held Israeli medical device company founded in 2002 and headquartered in Ness Ziona, Israel. The company develops and commercializes the MicronJet™ intradermal delivery platform — a hollow silicon crystal microneedle device manufactured using MEMS (Micro Electro Mechanical Systems) semiconductor-grade processes. The platform comprises MicronJet™ 600 (0.6mm, three micro-pyramids, flow equivalent to a 30G needle) for standard aesthetic, vaccine, and therapeutic applications, and MicronJet™ 800 (0.8mm, flow equivalent to a 27G needle) optimized for higher-viscosity formulations and hair restoration, launched in January 2026. NANOSOFT™, a private-label co-branded device with FILLMED, extends the platform into aesthetics in 60+ countries.

NanoPass serves two primary customer segments: medical aesthetics (aesthetic physicians, dermatologists, and clinics using the device for skin boosters, Botox, PRP, mesotherapy, dermal fillers, and lidocaine) and pharmaceutical/biotechnology companies (vaccine developers, immunotherapy researchers, and biologic drug developers seeking dose sparing and improved immunogenicity). Revenue is generated through hardware sales of MicronJet™ devices via direct B2B sales and a network of exclusive regional distribution partners, supplemented by licensing and private-label/co-branding arrangements (e.g., NANOSOFT™ with FILLMED).

The company operates in over 30 countries with regulatory approvals in major markets including the US (FDA), EU (CE), Canada, China (NMPA), Brazil (ANVISA), Korea (KFDA), Russia, Turkey, Australia, and Hong Kong. Distribution is primarily channel-led: Crescita Therapeutics holds exclusive rights for Canada, Aesthetic Management Partners (AMP) for the US, and YNC Medical for China (where more than 10,000 doctors have been trained). Manufacturing is anchored by a longstanding foundry relationship with Micro2Nano (M2N). Backed by West Pharmaceutical Services (strategic investor since 2016) and Awz Ventures (lead investor in the July 2024 $6M round), NanoPass reports a clinical evidence base of 70+ trials, 30,000+ injections, and ~7,500 patients.

Short descriptiontext

NanoPass Technologies is an Israeli medical device company developing the MicronJet™ MEMS-based hollow silicon crystal microneedle platform for virtually pain-free intradermal delivery. It serves aesthetic physicians and pharmaceutical/biotech companies across 30+ countries via distribution partners and licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNess Ziona, Israel
HQ citystring
Ness Ziona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microneedle drug delivery, intradermal delivery devices, MEMS medical devices, aesthetic injection devices, vaccine delivery technology
Industry2 codes
PRIMARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices (Intradermal Delivery / Microneedle)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

NanoPass generates revenue primarily through the sale of its MicronJet™ intradermal delivery devices (MicronJet™ 600 and MicronJet™ 800) via direct commercial sales and distribution partnerships across over 30 countries.

2Licensing and Co-branding
TypeLicensing Royalties
Description

NanoPass licenses its microneedle technology to aesthetic and pharmaceutical partners through private label agreements. Examples include NANOSOFT™ with FILLMED for aesthetics. The company also grants non-exclusive device access to pharmaceutical partners for clinical supply (e.g., Immune Design for oncology immunotherapy).

nanopass.com
3Distribution Agreement Revenue
TypeHardware Sales
Description

NanoPass expands market reach through exclusive distribution agreements with regional partners such as Crescita (Canada) and AMP (USA), generating revenue through product sales to these channel partners.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details2 tiers
1MicronJet™ 600 (0.6mm) — for skin rejuvenation, scars, pigmentation, hyperhidrosis, local anesthesia
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. Sold via distribution partners and direct B2B channels.

nanopass.com
2MicronJet™ 800 (0.8mm) — optimized for high-viscosity formulations and hair restoration treatments
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. Sold via distribution partners and direct B2B channels.

nanopass.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MicronJet
Description

Intradermal delivery device platform featuring hollow silicon crystal microneedles for pain-free drug and vaccine delivery, including MicronJet 600 (0.6mm) and MicronJet 800 (0.8mm) models

nanopass.com
+1 more record
Core offering1 text field

NanoPass Technologies designs, manufactures, and commercializes the MicronJet™ intradermal delivery platform — MEMS-based hollow silicon crystal microneedle devices available in 0.6mm (MicronJet™ 600) and 0.8mm (MicronJet™ 800) variants. These devices deliver therapeutics, vaccines, and aesthetic products shallow into the dermis with high consistency and minimal pain. NanoPass sells directly to pharma/biotech companies for clinical co-development and to aesthetic physicians/dermatologists, and distributes via exclusive regional partners across 30+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 99% bleb formation rate (>6mm) across over 1,000 injections on more than 800 subjects
+5 more records
Product overview1 text field

NanoPass Technologies offers the MicronJet™ intradermal delivery product platform, consisting of hardware-based microneedle devices for intradermal injection. The platform includes two primary products: MicronJet™ 600 (0.6mm) for standard aesthetic, vaccine, and therapeutic applications; and MicronJet™ 800 (0.8mm) for higher viscosity formulations and hair restoration treatments. Both devices leverage MEMS technology with silicon crystal delivery pyramids. The company also offers NANOSOFT™, a private-label version co-branded with FILLMED for aesthetic use. All products enable consistent, virtually pain-free intradermal delivery of substances approved for this route.

Product and service3 records
1MicronJet™ 600
CategoryIntradermal microneedle delivery device
Description

A 0.6mm intradermal delivery device with three hollow pyramid-shaped silicon crystal microneedles manufactured using semiconductor-grade MEMS technology. Designed for consistent, virtually pain-free delivery of aesthetic formulations, vaccines, and therapeutics. Suitable for skin rejuvenation, scars, pigmentation, hyperhidrosis, local anesthesia, and vaccine dose sparing. Flow rate equivalent to a 30-gauge needle.

2MicronJet™ 800
CategoryIntradermal microneedle delivery device
Description

A 0.8mm intradermal delivery device with three hollow pyramid-shaped silicon crystal microneedles optimized for medium-to-high viscosity formulations. Flow rate equivalent to a 27-gauge needle while maintaining precise intradermal depth. Particularly suited for hair restoration treatments, thicker skin areas, and applications requiring higher viscosity delivery.

3NANOSOFT™
CategoryPrivate label / co-branded microneedle device
Description

A private label, co-branded version of the MicronJet microneedle device developed with FILLMED (Laboratoires Filorga Medical) for use with NCTF® 135 HA polyrevitalizing solution in aesthetic treatments. Features three 0.6mm hollow pyramid-shaped microneedles produced using MEMS technology for nearly painless, shallow intradermal delivery. Distributed by FILLMED in over 60 countries.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Distribution Partners (Singapore, Mexico, Colombia, Australia)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-26
Description

NanoPass signed four new distribution agreements in November 2025 expanding commercial presence into Singapore, Mexico, Colombia, and Australia. These additions brought the total country coverage to over 30 countries, joining 28 channels established in the prior year across the US, Canada, Italy, France, Spain, and the UK.

nanopass.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-08-19
Description

Crescita Therapeutics signed an exclusive distribution agreement with NanoPass to launch and distribute the MicronJet™ 600 intradermal injection device in Canada, pending Health Canada approval expected in H1 2025. Crescita is a growth-oriented Canadian commercial dermatology company (TSX: CTX, OTC: CRRTF).

3YNC Medical
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-02-07
Description

YNC Medical is the premier partner of NanoPass in the medical market in China. YNC has worked with KOLs in more than 20 provinces and conducted training and academic communications with over 10,000 doctors and medical workers, supporting NanoPass's intradermal delivery platform and research institutions.

nanopass.com
4Emergex
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-01-26
Description

Emergex initiated a Phase I clinical study (naNO-COVID) using NanoPass's MicronJet® 600 for its synthetic T-cell adaptive COVID-19 vaccine. The partnership demonstrates that MicronJet™ can reduce vaccine doses and improve immune responses across vaccine platforms including mRNA, viral vectors, and proteins.

nanopass.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-12-22
Description

NanoPass and M2N entered a strategic development and foundry agreement for the design and production of NanoPass's proprietary MEMS-based microneedles. M2N has been integral to NanoPass's manufacturing since 2007, providing high-quality foundry services, ingenuity, and quick turnaround on development projects.

6Aesthetic Management Partners (AMP)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-12-19
Description

AMP and NanoPass signed an agreement to commercialize MicronJet® 600 intradermal delivery device in the US aesthetic market. The partnership provides dermatologists and aesthetic physicians with a safe, nearly painless, shallow, and consistent intradermal delivery device.

nanopass.com
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-04-03
Description

FILLMED and NanoPass signed a private label agreement to co-brand NanoPass's microneedle device as NANOSOFT™ for use with FILLMED's NCTF® 135 HA polyrevitalizing solution for aesthetic treatments. NANOSOFT™ was launched in Europe in May 2019 following AMWC Monaco. FILLMED distributes in over 60 countries.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2017-02-14
Description

IDRI and NanoPass signed a collaboration agreement to develop and test a Zika vaccine using replicating viral RNA (rvRNA) construct administered intradermally via MicronJet™. This builds on nearly a decade of collaboration on multiple global health vaccine programs. IDRI received $491,000 in NIH funding for the Zika vaccine development.

9Immune Design
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-09-08
Description

NanoPass entered a clinical supply and support agreement to provide MicronJet™ for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform. The non-exclusive agreement covers all of Immune Design's cancer immunotherapy programs globally.

nanopass.com
10Circassia
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2011-09-19
Description

Circassia licensed NanoPass's MicronJet™ microneedle intradermal delivery system for use with its ToleroMune Allergy T-Cell Vaccines (cat, ragweed, and other allergy therapies). The partnership aimed to enhance allergy immunotherapy delivery by targeting the skin's high concentration of antigen-presenting cells.

nanopass.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vaxxas develops high-density microarray patch (HD-MAP) technology for needle-free vaccine and biologic delivery. It is the most direct intradermal vaccine delivery peer to NanoPass's MicronJet, targeting the same pharmaceutical partners and global health use cases.

TypeDirect peer
Description

PharmaJet markets FDA-cleared needle-free jet injector systems (Tropis, Stratis) for intradermal and intramuscular vaccine delivery. It competes directly with MicronJet in dose-sparing intradermal vaccine applications and is also backed by WHO/PATH for global health deployment.

TypeBroad incumbent
Description

BD is a global medical device giant with an intradermal injection device (BD Soluvia) used for flu vaccine delivery and broad pharmaceutical systems / prefilled syringe offerings. It represents the scaled incumbent alternative to NanoPass's MicronJet for intradermal delivery.

TypeBroad incumbent
Description

West Pharma is the global leader in injectable drug containment and delivery components and is a strategic investor in NanoPass. It offers elastomeric components, prefilled syringe systems, and auto-injector platforms overlapping with NanoPass's intradermal delivery focus.

TypeBroad incumbent
Description

Kindeva is a leading contract drug delivery developer with microneedle and transdermal capabilities inherited from 3M. It serves as a broad incumbent developing microneedle-based drug and vaccine delivery solutions for pharma partners, competing for similar pharmaceutical R&D collaborations.

TypeBroad incumbent
Description

LTS Lohmann is a German-headquartered leader in transdermal therapeutic systems and microneedle-based drug delivery. It is a broad incumbent that develops and manufactures microneedle patches for pharmaceutical partners, overlapping with NanoPass's therapeutic and vaccine delivery applications.

TypeEmerging player
Description

Corium pioneered commercial microneedle-based transdermal drug delivery (e.g., transdermal sumatriptan, Corplex technology). It is an emerging player whose microneedle patch technology overlaps with NanoPass's intradermal delivery mission, particularly in CNS and other therapeutic areas.

TypeEmerging player
Description

Micron Biomedical develops dissolvable microneedle technology for vaccines (including measles-rubella, influenza, and polio) supported by Bill & Melinda Gates Foundation. It is an emerging peer directly competing for the same global health dose-sparing vaccine opportunity as NanoPass.

TypeEmerging player
Description

Debiotech is a Swiss medical device company developing MEMS-based microneedle and patch-based drug delivery systems. It overlaps with NanoPass's hollow microneedle technology and pharmaceutical partnership model.

TypeEmerging player
Description

Zosano Pharma develops microneedle transdermal delivery systems (its intracutaneous microarray patch technology) for therapeutic indications including migraines. It is an emerging player using microneedle patches for systemic drug delivery, comparable in modality to NanoPass's intradermal delivery platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NanoPass Technologies

Medical Devices (Intradermal Delivery / Microneedle)nanopass.com

NanoPass Technologies is an Israeli medical device company developing the MicronJet™ MEMS-based hollow silicon crystal microneedle platform for virtually pain-free intradermal delivery. It serves aesthetic physicians and pharmaceutical/biotech companies across 30+ countries via distribution partners and licensing.

What NanoPass Technologies does

NanoPass Technologies Ltd. is a privately held Israeli medical device company founded in 2002 and headquartered in Ness Ziona, Israel. The company develops and commercializes the MicronJet™ intradermal delivery platform — a hollow silicon crystal microneedle device manufactured using MEMS (Micro Electro Mechanical Systems) semiconductor-grade processes. The platform comprises MicronJet™ 600 (0.6mm, three micro-pyramids, flow equivalent to a 30G needle) for standard aesthetic, vaccine, and therapeutic applications, and MicronJet™ 800 (0.8mm, flow equivalent to a 27G needle) optimized for higher-viscosity formulations and hair restoration, launched in January 2026. NANOSOFT™, a private-label co-branded device with FILLMED, extends the platform into aesthetics in 60+ countries.

NanoPass serves two primary customer segments: medical aesthetics (aesthetic physicians, dermatologists, and clinics using the device for skin boosters, Botox, PRP, mesotherapy, dermal fillers, and lidocaine) and pharmaceutical/biotechnology companies (vaccine developers, immunotherapy researchers, and biologic drug developers seeking dose sparing and improved immunogenicity). Revenue is generated through hardware sales of MicronJet™ devices via direct B2B sales and a network of exclusive regional distribution partners, supplemented by licensing and private-label/co-branding arrangements (e.g., NANOSOFT™ with FILLMED).

The company operates in over 30 countries with regulatory approvals in major markets including the US (FDA), EU (CE), Canada, China (NMPA), Brazil (ANVISA), Korea (KFDA), Russia, Turkey, Australia, and Hong Kong. Distribution is primarily channel-led: Crescita Therapeutics holds exclusive rights for Canada, Aesthetic Management Partners (AMP) for the US, and YNC Medical for China (where more than 10,000 doctors have been trained). Manufacturing is anchored by a longstanding foundry relationship with Micro2Nano (M2N). Backed by West Pharmaceutical Services (strategic investor since 2016) and Awz Ventures (lead investor in the July 2024 $6M round), NanoPass reports a clinical evidence base of 70+ trials, 30,000+ injections, and ~7,500 patients.

NanoPass Technologies firmographics

Firmographics
Name
NanoPass Technologies
Legal name
NanoPass Technologies Ltd.
Website
https://nanopass.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
NanoPass Technologies is an Israeli medical device company developing the MicronJet™ MEMS-based hollow silicon crystal microneedle platform for virtually pain-free intradermal delivery. It serves aesthetic physicians and pharmaceutical/biotech companies across 30+ countries via distribution partners and licensing.
Ownership category
akta.pro rank

NanoPass Technologies industry classification

Industry
Product category
Medical Devices (Intradermal Delivery / Microneedle)
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Microneedle drug delivery
  • Intradermal delivery devices
  • MEMS medical devices
  • Aesthetic injection devices
  • Vaccine delivery technology

Where NanoPass Technologies is headquartered

Location

Headquarters

HQ city
Ness Ziona
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

NanoPass Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Medical Device Sales: NanoPass generates revenue primarily through the sale of its MicronJet™ intradermal delivery devices (MicronJet™ 600 and MicronJet™ 800) via direct commercial sales and distribution partnerships across over 30 countries.
  2. Licensing and Co-branding: NanoPass licenses its microneedle technology to aesthetic and pharmaceutical partners through private label agreements. Examples include NANOSOFT™ with FILLMED for aesthetics. The company also grants non-exclusive device access to pharmaceutical partners for clinical supply (e.g., Immune Design for oncology immunotherapy).
  3. Distribution Agreement Revenue: NanoPass expands market reach through exclusive distribution agreements with regional partners such as Crescita (Canada) and AMP (USA), generating revenue through product sales to these channel partners.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMicronJet™ 600 (0.6mm) — for skin rejuvenation, scars, pigmentation, hyperhidrosis, local anesthesia
OtherMulti-year contractMicronJet™ 800 (0.8mm) — optimized for high-viscosity formulations and hair restoration treatments

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

NanoPass Technologies product offering

Product offering

Core offering

NanoPass Technologies designs, manufactures, and commercializes the MicronJet™ intradermal delivery platform — MEMS-based hollow silicon crystal microneedle devices available in 0.6mm (MicronJet™ 600) and 0.8mm (MicronJet™ 800) variants. These devices deliver therapeutics, vaccines, and aesthetic products shallow into the dermis with high consistency and minimal pain. NanoPass sells directly to pharma/biotech companies for clinical co-development and to aesthetic physicians/dermatologists, and distributes via exclusive regional partners across 30+ countries.

Product overview

NanoPass Technologies offers the MicronJet™ intradermal delivery product platform, consisting of hardware-based microneedle devices for intradermal injection. The platform includes two primary products: MicronJet™ 600 (0.6mm) for standard aesthetic, vaccine, and therapeutic applications; and MicronJet™ 800 (0.8mm) for higher viscosity formulations and hair restoration treatments. Both devices leverage MEMS technology with silicon crystal delivery pyramids. The company also offers NANOSOFT™, a private-label version co-branded with FILLMED for aesthetic use. All products enable consistent, virtually pain-free intradermal delivery of substances approved for this route.

Differentiator

Problem solved

Functional benefit

Brands

  • MicronJet: Intradermal delivery device platform featuring hollow silicon crystal microneedles for pain-free drug and vaccine delivery, including MicronJet 600 (0.6mm) and MicronJet 800 (0.8mm) models
  • NANOSOFT

Products and services

  • MicronJet™ 600 A 0.6mm intradermal delivery device with three hollow pyramid-shaped silicon crystal microneedles manufactured using semiconductor-grade MEMS technology. Designed for consistent, virtually pain-free delivery of aesthetic formulations, vaccines, and therapeutics. Suitable for skin rejuvenation, scars, pigmentation, hyperhidrosis, local anesthesia, and vaccine dose sparing. Flow rate equivalent to a 30-gauge needle.
  • MicronJet™ 800 A 0.8mm intradermal delivery device with three hollow pyramid-shaped silicon crystal microneedles optimized for medium-to-high viscosity formulations. Flow rate equivalent to a 27-gauge needle while maintaining precise intradermal depth. Particularly suited for hair restoration treatments, thicker skin areas, and applications requiring higher viscosity delivery.
  • NANOSOFT™ A private label, co-branded version of the MicronJet microneedle device developed with FILLMED (Laboratoires Filorga Medical) for use with NCTF® 135 HA polyrevitalizing solution in aesthetic treatments. Features three 0.6mm hollow pyramid-shaped microneedles produced using MEMS technology for nearly painless, shallow intradermal delivery. Distributed by FILLMED in over 60 countries.

Quantifiable outcome

  • 99% bleb formation rate (>6mm) across over 1,000 injections on more than 800 subjects
  • +5 more outcomes

Companies that use NanoPass Technologies

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

NanoPass Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NanoPass Technologies partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and minor.

  • Distribution Partners (Singapore, Mexico, Colombia, Australia)coreChannel Partner/ Reseller/ Distributor · 26 November 2025NanoPass signed four new distribution agreements in November 2025 expanding commercial presence into Singapore, Mexico, Colombia, and Australia. These additions brought the total country coverage to over 30 countries, joining 28 channels established in the prior year across the US, Canada, Italy, France, Spain, and the UK.
  • Crescita Therapeutics Inc.coreChannel Partner/ Reseller/ Distributor · 19 August 2024Crescita Therapeutics signed an exclusive distribution agreement with NanoPass to launch and distribute the MicronJet™ 600 intradermal injection device in Canada, pending Health Canada approval expected in H1 2025. Crescita is a growth-oriented Canadian commercial dermatology company (TSX: CTX, OTC: CRRTF).
  • YNC MedicalmajorChannel Partner/ Reseller/ Distributor · 7 February 2022YNC Medical is the premier partner of NanoPass in the medical market in China. YNC has worked with KOLs in more than 20 provinces and conducted training and academic communications with over 10,000 doctors and medical workers, supporting NanoPass's intradermal delivery platform and research institutions.
  • EmergexmajorStrategic or Co-development Partner · 26 January 2022Emergex initiated a Phase I clinical study (naNO-COVID) using NanoPass's MicronJet® 600 for its synthetic T-cell adaptive COVID-19 vaccine. The partnership demonstrates that MicronJet™ can reduce vaccine doses and improve immune responses across vaccine platforms including mRNA, viral vectors, and proteins.
  • Micro2Nano (M2N)coreTechnology or Integration · 22 December 2021NanoPass and M2N entered a strategic development and foundry agreement for the design and production of NanoPass's proprietary MEMS-based microneedles. M2N has been integral to NanoPass's manufacturing since 2007, providing high-quality foundry services, ingenuity, and quick turnaround on development projects.
  • Aesthetic Management Partners (AMP)coreChannel Partner/ Reseller/ Distributor · 19 December 2021AMP and NanoPass signed an agreement to commercialize MicronJet® 600 intradermal delivery device in the US aesthetic market. The partnership provides dermatologists and aesthetic physicians with a safe, nearly painless, shallow, and consistent intradermal delivery device.
  • FILLMED (Laboratoires Filorga Medical)majorOEM/ Whitelabel/ Licensing Partner · 3 April 2019FILLMED and NanoPass signed a private label agreement to co-brand NanoPass's microneedle device as NANOSOFT™ for use with FILLMED's NCTF® 135 HA polyrevitalizing solution for aesthetic treatments. NANOSOFT™ was launched in Europe in May 2019 following AMWC Monaco. FILLMED distributes in over 60 countries.
  • IDRI (Infectious Disease Research Institute)majorStrategic or Co-development Partner · 14 February 2017IDRI and NanoPass signed a collaboration agreement to develop and test a Zika vaccine using replicating viral RNA (rvRNA) construct administered intradermally via MicronJet™. This builds on nearly a decade of collaboration on multiple global health vaccine programs. IDRI received $491,000 in NIH funding for the Zika vaccine development.
  • Immune DesignmajorStrategic or Co-development Partner · 8 September 2015NanoPass entered a clinical supply and support agreement to provide MicronJet™ for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform. The non-exclusive agreement covers all of Immune Design's cancer immunotherapy programs globally.
  • CircassiaminorStrategic or Co-development Partner · 19 September 2011Circassia licensed NanoPass's MicronJet™ microneedle intradermal delivery system for use with its ToleroMune Allergy T-Cell Vaccines (cat, ragweed, and other allergy therapies). The partnership aimed to enhance allergy immunotherapy delivery by targeting the skin's high concentration of antigen-presenting cells.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

NanoPass Technologies competitors and assessment

Company assessment

Direct peers

  • Vaxxas: Vaxxas develops high-density microarray patch (HD-MAP) technology for needle-free vaccine and biologic delivery. It is the most direct intradermal vaccine delivery peer to NanoPass's MicronJet, targeting the same pharmaceutical partners and global health use cases.
  • PharmaJet: PharmaJet markets FDA-cleared needle-free jet injector systems (Tropis, Stratis) for intradermal and intramuscular vaccine delivery. It competes directly with MicronJet in dose-sparing intradermal vaccine applications and is also backed by WHO/PATH for global health deployment.

Broad incumbents

  • Becton, Dickinson and Company (BD): BD is a global medical device giant with an intradermal injection device (BD Soluvia) used for flu vaccine delivery and broad pharmaceutical systems / prefilled syringe offerings. It represents the scaled incumbent alternative to NanoPass's MicronJet for intradermal delivery.
  • West Pharmaceutical Services: West Pharma is the global leader in injectable drug containment and delivery components and is a strategic investor in NanoPass. It offers elastomeric components, prefilled syringe systems, and auto-injector platforms overlapping with NanoPass's intradermal delivery focus.
  • Kindeva Drug Delivery (formerly 3M Drug Delivery Systems): Kindeva is a leading contract drug delivery developer with microneedle and transdermal capabilities inherited from 3M. It serves as a broad incumbent developing microneedle-based drug and vaccine delivery solutions for pharma partners, competing for similar pharmaceutical R&D collaborations.
  • LTS Lohmann Therapie-Systeme: LTS Lohmann is a German-headquartered leader in transdermal therapeutic systems and microneedle-based drug delivery. It is a broad incumbent that develops and manufactures microneedle patches for pharmaceutical partners, overlapping with NanoPass's therapeutic and vaccine delivery applications.

Emerging players

  • Corium (now part of Gurnet Point / Lotte): Corium pioneered commercial microneedle-based transdermal drug delivery (e.g., transdermal sumatriptan, Corplex technology). It is an emerging player whose microneedle patch technology overlaps with NanoPass's intradermal delivery mission, particularly in CNS and other therapeutic areas.
  • Micron Biomedical: Micron Biomedical develops dissolvable microneedle technology for vaccines (including measles-rubella, influenza, and polio) supported by Bill & Melinda Gates Foundation. It is an emerging peer directly competing for the same global health dose-sparing vaccine opportunity as NanoPass.
  • Debiotech: Debiotech is a Swiss medical device company developing MEMS-based microneedle and patch-based drug delivery systems. It overlaps with NanoPass's hollow microneedle technology and pharmaceutical partnership model.
  • Zosano Pharma: Zosano Pharma develops microneedle transdermal delivery systems (its intracutaneous microarray patch technology) for therapeutic indications including migraines. It is an emerging player using microneedle patches for systemic drug delivery, comparable in modality to NanoPass's intradermal delivery platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

NanoPass Technologies social profiles

Digital presence

NanoPass Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NanoPass Technologies leadership team

Management profile

Number of profiles

Profiles8 records

NanoPass Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NanoPass Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoPass Technologies

What does NanoPass Technologies do?

NanoPass Technologies designs, manufactures, and commercializes the MicronJet™ intradermal delivery platform — MEMS-based hollow silicon crystal microneedle devices available in 0.6mm (MicronJet™ 600) and 0.8mm (MicronJet™ 800) variants. These devices deliver therapeutics, vaccines, and aesthetic products shallow into the dermis with high consistency and minimal pain. NanoPass sells directly to pharma/biotech companies for clinical co-development and to aesthetic physicians/dermatologists, and distributes via exclusive regional partners across 30+ countries.

Is NanoPass Technologies a public or private company?

NanoPass Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was NanoPass Technologies founded?

NanoPass Technologies was founded in 2002. It employs 11 to 50 people.

Where is NanoPass Technologies based?

NanoPass Technologies is headquartered in Ness Ziona, Israel, in the Middle East region.

How does NanoPass Technologies make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are licensing and Co-branding and distribution Agreement Revenue.

Who are NanoPass Technologies's main competitors?

Direct peers on record are Vaxxas and PharmaJet. Broad incumbents are Becton, Dickinson and Company (BD), West Pharmaceutical Services, Kindeva Drug Delivery (formerly 3M Drug Delivery Systems) and LTS Lohmann Therapie-Systeme. Emerging players are Corium (now part of Gurnet Point / Lotte), Micron Biomedical, Debiotech and Zosano Pharma.

Does NanoPass Technologies have an API?

No public API is recorded for NanoPass Technologies.

What industry is NanoPass Technologies in?

NanoPass Technologies's product category is Medical Devices (Intradermal Delivery / Microneedle). Its primary akta.pro industry code is HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deNurExone Biologic: Kommerzialisierung der "Super-Exosomen"NurExone Biologic signed a MOU with NanoPass Technologies to evaluate MicronJet integration for its exosome formulations in eye and skin applications. The company also signed a MOU with Made Scientific for US GMP production and commercial supply. Clinical trials for ExoPTEN are planned for late 2026 or early 2027.FinanzNachrichten.deKickoff-News: NurExone Biologic mit wegweisendem Schritt!NurExone Biologic signed a MOU with NanoPass Technologies to evaluate MicronJet integration for exosome delivery in eye and skin applications. The company also plans a US-GMP production partnership with Made Scientific and aims to submit an IND for ExoPTEN clinical trials by late 2026 or early 2027.BioSpaceNurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin ApplicationsNurExone and NanoPass Technologies signed an MOU to evaluate MicronJet's intradermal delivery platform with NurExone's exosome formulations for eye and skin applications. The collaboration includes a preclinical study for suprachoroidal delivery in ophthalmology and intradermal delivery for skincare, with each party funding its own activities. The MOU does not obligate a definitive commercial agreement.openPR.comMicroneedle Drug Delivery Systems Market Players - Competitive Positioning, Strategic Strengths & Investor OutlookThe global microneedle drug delivery systems market is rapidly growing, with projections reaching USD 10.85 billion by 2032, driven by technological advancements, strategic collaborations, and increasing demand for minimally invasive drug delivery methods. Major companies like 3M, Becton, Dickinson, Zosano Pharma, and Nanopass Technologies are actively investing in product innovation, geographic expansion, and strategic partnerships.PR NewswireNanoPass Technologies Expands Product Portfolio to Advance Intradermal DeliveryNanoPass Technologies Ltd. announced the launch of MicronJet™ 800, a new intradermal delivery device, during IMCAS World 2026 in Paris. The device extends its portfolio for aesthetic and dermatological applications, including non-surgical hair restoration, and offers advantages such as virtually pain-free injections and precise delivery for thicker skin areas.Mexico Business NewsNanoPass Brings Minimally Invasive MicronJet to MexicoNanoPass Technologies has expanded into Mexico through a new distribution agreement for its MicronJet intradermal delivery platform, extending its global commercial presence to over 30 countries. The MicronJet platform uses silicon-crystal pyramids less than 1mm in length to deliver treatments precisely into the dermis, replacing traditional needles, and has been evaluated in more than 70 clinical studies. The expansion aligns with growing demand for minimally invasive dermatology in Latin America, and NanoPass is also advancing clinical studies in vaccines, immunotherapy, local anesthesia, and ocular applications.PR NewswireMicronJet™ Continues Its Journey to Become the Gold Standard in Intradermal DeliveryNanoPass Technologies announced four new distribution agreements expanding into Singapore, Mexico, Colombia, and Australia, bringing its total market presence to over 30 countries with 28 channels established in the past year. The MicronJet platform, which uses silicon-crystal delivery pyramids under 1mm in length, is now positioned as the company's flagship product for intradermal delivery in aesthetic and medical applications. The company continues advancing clinical studies with pharmaceutical partners in vaccines, immunotherapy, and cell therapy while targeting global gold standard status for its proprietary technology.Mpo-magCrescita Expands Medical Aesthetic Portfolio in CanadaCrescita Therapeutics Inc. has signed an exclusive distribution agreement with NanoPass Technologies Ltd. to launch and distribute the MicronJet 600 intradermal injection device in Canada, pending Health Canada approval expected in the first half of 2025. The device uses MEMS technology with three silicon crystal delivery pyramids to provide virtually pain-free and precise aesthetic injections. NanoPass CEO Daniel Levitats called the collaboration an exciting step toward commercial growth goals.PR NewswireNanoPass Technologies Secures Awz Ventures' $4M Investment, Signaling Growth and Innovation in Intradermal Delivery TechnologyNanoPass Technologies secured a $4 million investment from Awz Ventures as part of a $6 million funding round. The company appointed Daniel Levitats as CEO and highlighted its MicronJet™ intradermal delivery platform, which is FDA cleared and smaller than 1 mm. Awz's investment supports multi-stage funding and M&A opportunities.